Document is current
Any future updates will be listed below
-
Authors
Huang, Yun
Sulek, Karolina
Stinson, Sara E. https://orcid.org/0000-0002-1491-9179
Holm, Louise Aas
Kim, Min https://orcid.org/0000-0002-8769-4804
Trost, Kajetan
Hooshmand, Kourosh
Lund, Morten Asp Vonsild
Fonvig, Cilius E.
Juel, Helene Bæk
Nielsen, Trine https://orcid.org/0000-0002-2066-7895
Ängquist, Lars
Rossing, Peter https://orcid.org/0000-0002-1531-4294
Thiele, Maja https://orcid.org/0000-0003-1854-1924
Krag, Aleksander https://orcid.org/0000-0002-9598-4932
Holm, Jens-Christian https://orcid.org/0000-0003-4653-342X
Legido-Quigley, Cristina https://orcid.org/0000-0002-4018-214X
Hansen, Torben https://orcid.org/0000-0001-8748-3831
-
Funding
Funding for this research was provided by:
Innovationsfonden (0603-00484B)
Innovationsfonden (0603-00484B)
Novo Nordisk Fonden (NNF15OC0016544)
Novo Nordisk Fonden (NNF15OC0016692)
Novo Nordisk Fonden (NNF18CC0034900)
Novo Nordisk Fonden (NNF23SA0084103)
Novo Nordisk Fonden (NNF 0074491)
Novo Nordisk Fonden (NNF18CC0033668)
Novo Nordisk Fonden (NNF20SA0067242)
Lundbeckfonden (LFR344-2020-989)
- License Information
-
More Information
Article History
Received: 15 March 2024
Accepted: 30 August 2024
First Online: 20 September 2024
Competing interests
: The data and paper were prepared while K.S. was employed at the Steno Diabetes Center Copenhagen. In the process of revision and publication, K.S. has started a position at Novo Nordisk. C.L.-Q. has received consultancy fees from Pfizer. C.L.-Q. has received honoraria, travel or speakers’ fees from Biogen and research funds from Pfizer and Novo Nordisk. C.L.-Q. is the director of the company BrainLogia. All of these activities are unrelated to this study. The other authors declare no competing interests.
